Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 1:13 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1273–1296 of 26,236 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Cancer Patient Clear all
Completed No phase listed Observational

Resiliency in Patients Undergoing Radical Cystectomy for Bladder Cancer

NCT06337305
View directory record Official record
Conditions
Bladder Cancer
Interventions
Not listed
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 15, 2024 · Synced Oct 27, 2026, 1:13 AM EDT
Terminated No phase listed Observational

Comparison of Contrast Agents for MRI Perfusion Analysis in Brain Tumor Patients

NCT02095353
View directory record Official record
Conditions
Central Nervous System Neoplasms
Interventions
Not listed
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Aug 23, 2023 · Synced Oct 27, 2026, 1:13 AM EDT
Completed Not applicable Interventional

Guided Imagery in the Perioperative Period in Gynecologic Oncology Patients

NCT02444195
View directory record Official record
Conditions
Uterine Cervical Neoplasms, Uterine Neoplasms, Ovarian Neoplasms, Urogenital Neoplasms, Fallopian Tube Neoplasms
Interventions
Guided Imagery With Audio Media
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older · Female only
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 20, 2017 · Synced Oct 27, 2026, 1:13 AM EDT
Completed Not applicable Interventional Results available

Lymph Node Mapping in Patients With Endometrial Cancer

NCT01818739
View directory record Official record
Conditions
Endometrial Cancer
Interventions
sentinel lymph node detection, indocyanine green solution, isosulfan blue, sentinel lymph node biopsy
Procedure · Drug
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years to 85 Years · Female only
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
2
States / cities
New Haven, Connecticut • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 22, 2023 · Synced Oct 27, 2026, 1:13 AM EDT
Completed Not applicable Interventional

Response Monitoring Trial in Patients With Suspected Recurrence of Glioblastoma

NCT01813877
View directory record Official record
Conditions
Glioma, Glioblastoma
Interventions
FDOPA PET/CT
Radiation
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years to 99 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 27, 2020 · Synced Oct 27, 2026, 1:13 AM EDT
Completed Early Phase 1 Interventional Results available

Serologic Response to SHINGRIX Vaccine in Patients With CLL and WM Treated With BTK Inhibitors

NCT03771157
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia (CLL), Waldenstrom Macroglobulinemia (WM)
Interventions
Shingrix vaccine
Drug
Lead sponsor
University of Rochester
Other
Eligibility
50 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Mar 15, 2024 · Synced Oct 27, 2026, 1:13 AM EDT
Active, not recruiting No phase listed Observational

Seizure Control as a New Metric in Assessing Efficacy of Tumor Treatment in Patients With Low Grade Glioma

NCT04553757
View directory record Official record
Conditions
Brain Neoplasm, Low Grade Glioma, Seizure Disorder
Interventions
Survey Administration
Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 27, 2026, 1:13 AM EDT
Completed No phase listed Observational

The Management of Postoperative Craniotomy Pain in Pediatric Patients

NCT01576601
View directory record Official record
Conditions
Post Craniotomy Surgery, Cancer, Epilepsy, Vascular Malformations, Craniofacial Reconstructive Surgery
Interventions
Not listed
Lead sponsor
Johns Hopkins University
Other
Eligibility
Up to 18 Years
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
3
States / cities
Baltimore, Maryland • Boston, Massachusetts • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 11, 2017 · Synced Oct 27, 2026, 1:13 AM EDT
Terminated Phase 2 Interventional Results available

Advanced Non-Small Cell Lung Cancer Progressing After at Least One Prior Therapy For Metastatic Disease

NCT02469701
View directory record Official record
Conditions
Non-small Cell Lung Cancer, Lung Cancer, Metastatic Lung Cancer, NSCLC
Interventions
nivolumab and ablation
Drug
Lead sponsor
howard safran
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
2
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Feb 17, 2020 · Synced Oct 27, 2026, 1:13 AM EDT
Active, not recruiting Phase 2 Interventional

Phase II Study of Neoadjuvant Cetuximab and Cemiplimab in Patients Undergoing Surgery for HNSCC

NCT06855212
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma
Interventions
Cemiplimab, Cetuximab
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated May 20, 2026 · Synced Oct 27, 2026, 1:13 AM EDT
Completed Phase 1 Interventional

Liposomal Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin for the Treatment of Relapsed Refractory Pediatric Patients With Acute Myeloid Leukemia

NCT04915612
View directory record Official record
Conditions
Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia
Interventions
Gemtuzumab Ozogamicin, Liposome-encapsulated Daunorubicin-Cytarabine
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Up to 21 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 20, 2026 · Synced Oct 27, 2026, 1:13 AM EDT
Terminated Phase 2 Interventional Results available

Photodynamic Therapy With HPPH Compared to Standard of Care Surgery in Treating Patients With Oral Cavity Cancer

NCT03090412
View directory record Official record
Conditions
Stage I Oral Cavity Squamous Cell Carcinoma, Stage II Oral Cavity Squamous Cell Carcinoma
Interventions
HPPH, Laboratory Biomarker Analysis, Photodynamic Therapy, Quality-of-Life Assessment, Therapeutic Conventional Surgery
Drug · Other · Procedure
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
2
States / cities
Buffalo, New York • Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jun 2, 2022 · Synced Oct 27, 2026, 1:13 AM EDT
Completed Phase 3 Interventional

Meta-Iodobenzylguanidine (123I mIBG) Scintigraphy in Patients Being Evaluated for Phaeochromocytoma or Neuroblastoma

NCT00126412
View directory record Official record
Conditions
Pheochromocytoma, Neuroblastoma
Interventions
123I-mIBG (meta-iodobenzylguanidine)
Drug
Lead sponsor
GE Healthcare
Industry
Eligibility
Not listed
Enrollment
251 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated May 31, 2019 · Synced Oct 27, 2026, 1:13 AM EDT
Terminated Phase 1 Interventional Results available

A Pilot Study Assessing Intra-Metastasis Administration of Autologous KLH-pulsed Dendritic Cells With Tumoral Radiation Therapy in Patients With Metastatic Pancreatic Carcinoma

NCT00843830
View directory record Official record
Conditions
Metastatic Pancreatic Carcinoma
Interventions
tumoral irradiation, Dendritic cell vaccination
Radiation · Biological
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 8, 2015 · Synced Oct 27, 2026, 1:13 AM EDT
Completed Phase 4 Interventional

A Safety Evaluation of Drotrecogin Alfa (Activated) in Patients With Blood Cancer, Severe Infection Related to Bone Marrow Transplantation

NCT00067730
View directory record Official record
Conditions
Sepsis, Hematologic Neoplasms, Hematopoietic Stem Cell Transplantation, Infection
Interventions
Drotrecogin Alfa (activated)
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003
U.S. locations
5
States / cities
Denver, Colorado • Iowa City, Iowa • Manhassaet, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 7, 2007 · Synced Oct 27, 2026, 1:13 AM EDT
Completed Phase 2 Interventional Results available

Stem Cell Monitoring for CML Patients Undergoing Nilotinib Therapy

NCT02353728
View directory record Official record
Conditions
Chronic Myeloid Leukemia
Interventions
Nilotinib
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 25, 2022 · Synced Oct 27, 2026, 1:13 AM EDT
Completed Phase 1 Interventional

A Study of BNC105P Combined With Ibrutinib

NCT03454165
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia
Interventions
BNC105P, Ibrutinib
Combination Product
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Jan 4, 2023 · Synced Oct 27, 2026, 1:13 AM EDT
Suspended Phase 2 Interventional

Biological Therapy in Treating Patients With Primary or Advanced Glioma

NCT00003067
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
aldesleukin, lymphokine-activated killer cells
Biological
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
1
States / cities
Staten Island, New York
Source: ClinicalTrials.gov public record
Updated Feb 9, 2009 · Synced Oct 27, 2026, 1:13 AM EDT
Completed Phase 1 Interventional Results available

Treatment Duration Increment and Pharmacodynamic Study of CX-4945 in Patients With Basal Cell Carcinoma (BCC)

NCT03897036
View directory record Official record
Conditions
Carcinoma, Basal Cell
Interventions
CX-4945
Drug
Lead sponsor
Senhwa Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
6
States / cities
Scottsdale, Arizona • Aurora, Colorado • Tampa, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated May 20, 2025 · Synced Oct 27, 2026, 1:13 AM EDT
Completed Not applicable Interventional

Continuous Glucose Monitor Application After Hospital Discharge for the Improvement of Outcomes in Patients With Poorly Controlled Type 2 Diabetes and Active Cancer

NCT04938869
View directory record Official record
Conditions
Hematopoietic and Lymphoid System Neoplasm, Malignant Solid Neoplasm, Type 2 Diabetes Mellitus
Interventions
Educational Intervention, Medical Device Usage and Evaluation, Survey Administration
Other
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
Not listed
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 24, 2023 · Synced Oct 27, 2026, 1:13 AM EDT
Terminated Phase 2 Interventional Results available

An Open-Label, Randomized, Multicenter Trial of Encorafenib + Binimetinib Evaluating a Standard-dose and a High-dose Regimen in Patients With BRAFV600-mutant Melanoma Brain Metastasis

NCT03911869
View directory record Official record
Conditions
Brain Metastases
Interventions
encorafenib, binimetinib
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
11
States / cities
Los Angeles, California • San Francisco, California • Santa Monica, California + 3 more
Source: ClinicalTrials.gov public record
Updated May 31, 2023 · Synced Oct 27, 2026, 1:13 AM EDT
Not yet recruiting No phase listed Observational

Investigating Participation Patterns Among Stage IV Melanoma Patients

NCT06093594
View directory record Official record
Conditions
Stage IV Melanoma
Interventions
Not listed
Lead sponsor
Power Life Sciences Inc.
Industry
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 23, 2023 · Synced Oct 27, 2026, 1:13 AM EDT
Completed Not applicable Interventional

Aerobic and Strength Training Exercise in Improving Fitness and Arm Health During and After Radiation Therapy in Patients With Stage II-III Breast Cancer

NCT03102866
View directory record Official record
Conditions
Stage II Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
Interventions
Best Practice, Exercise Intervention, Quality-of-Life Assessment, Questionnaire Administration
Other · Behavioral
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
Female only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 14, 2023 · Synced Oct 27, 2026, 1:13 AM EDT
Active, not recruiting Phase 2 Interventional

Risk-Adapted Focal Proton Beam Radiation and/or Surgery in Patients With Low, Intermediate and High Risk Rhabdomyosarcoma Receiving Standard or Intensified Chemotherapy

NCT01871766
View directory record Official record
Conditions
Rhabdomyosarcoma
Interventions
Vincristine, Dactinomycin, Cyclophosphamide, Surgical Resection, Radiation, Bevacizumab, Sorafenib, Myeloid Growth Factor, Lymph Node Sampling, Irinotecan, Ifosfamide, Etoposide, Etoposide Phosphate, Doxorubicin, Dexrazoxane, ^1^1C-methionine
Drug · Procedure
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 21 Years
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2030
U.S. locations
4
States / cities
Jacksonville, Florida • Memphis, Tennessee • Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Oct 27, 2026, 1:13 AM EDT